Nebraska Medicaid DUR Board Meeting  
Tuesday, September 11, 2018  
DRAFT pending approval at November Meeting

DUR Board Members in Attendance:
Nichole Boggs, UNMC PharmD Candidate  
Kevin Borcher, RP  
Lynn Carlson, RP  
Shana Castillo, RP  
Eric Gall, RP  
Bruce Houghton, MD  
Norman Kelley, MD  
Madeline Leiter, CU PharmD Candidate  
Roger Mattson, RP  
Charlie Moore, RP  
Marcia Mueting, RP  
Kirk Muffly, MD  
David Randolph, RP  
Phil Vuchetich, RP

DUR Board members not in Attendance:
Susan Howard, MD  
Robert Wergin, MD

Guests in Attendance:
Jill Bot, RP Magellan Medicaid Administration  
Dane Ewald, UNMC PharmD Candidate  
Yangyang Gao, UNMC PharmD Candidate  
Jenny Minchow, RP Nebraska Medicaid & LTC Services  
Shannon Nelson, RP, WellCare of Nebraska (WC)  
Kevin Peterson, RP, Nebraska Total Care (NTC)  
Bernadette Ueda, RP, United Health Care (UHC)

Public Members in Attendance:
Rhianna Tortorige, Abbott Diabetes Care  
Melissa Basil, Abbvie  
Brad Brekke Bioverativ, Inc.  
Sean Parker, Bristol-Myers Squibb Co.  
Chris Guenther, Genentech  
Julie Brown, Harmony Biosciences  
Rhonda Clark, Indivior  
Dave Cecil, Johnson & Johnson  
Nick Boyer, Otsuka  
Rick Kegler, Otsuka  
Nancy Bell, Pfizer  
Susan Kelly, Spark Therapeutics  
Casey Johnson, Viiv Healthcare

I. Opening and Introductions
The meeting was called to order at 6:30 p.m. by DUR Director, Marcia Mueting. The Director noted that a copy of the Open Meeting Laws and the meeting materials were available. Public attendees were asked
to complete the sign-in sheet if they wished to be listed in the minutes as attending. Board members, guests and public attendees introduced themselves.

II. Declaration of Any Conflict of Interest Changes
No changes were declared.

III. Approval of the Agenda
A motion was made by Norman Kelley with a second from Charlie Moore to approve the agenda as presented. Vote as follows: Borcher-abstain, Carlson-yes, Castillo-yes, Gall-yes, Houghton-yes, Kelley-yes, Mattson-yes, Moore-yes, Muffly-yes, Randolph-yes and Vuchetich-yes. Motion carried.

IV. Approval of Minutes from July Meeting
A motion was made by Norman Kelley with a second from Bruce Houghton to approve the minutes as presented. Vote as follows: Borcher-abstain, Carlson-yes, Castillo-abstain, Gall-abstain, Houghton-yes, Kelley-yes, Mattson-abstain, Moore-yes, Muffly-yes, Randolph-abstain and Vuchetich-yes. Motion carried.

V. Update on Recommendations from July Meeting
No discussion.

VI. Retrospective DUR
A. Current Profile Review
1. Restricted Services (RS)
Marcia Mueting reported that in Fee-For-Service (FFS) the criteria for restricted services review is patients utilizing 6 or more prescribers and 3 or more pharmacies in a month. No patients met the criteria in July or August.

Kevin Peterson with NTC shared that in June, 23 patients met the criteria for review, 8 were removed from RS and 11 patients were added to case management. In July 16 patients met the criteria for review, 3 were removed from RS, 5 were added to RS and 9 were referred to case management. In August, 25 patients met the criteria for review, 2 were removed from RS, 7 were added to RS, and 17 were referred to case management.

Shannon Nelson with WC noted that in July, 30 patients met the criteria for review, 16 were referred to case management, 3 were added to RS and 9 patients required no action. There were 2 patients who were due for biennial review with 1 being removed from RS, and the other continued in RS. In August, 34 patients met the criteria for review, 14 were referred to case management, 3 were added to RS, 17 patients required no action.

Bernadette Ueda of UHC explained that the criteria for RS review is patients taking 1 or more of the 9 targeted medications, using 3 or more pharmacies, and utilizing 3 or more prescribers. In July, 15 patients met the criteria for review, 7 were added to RS, 8 were removed from RS. In August, 6 patients met the criteria for review, 3 were added to RS, 3 were removed. There is a total of 131 patients in RS for UHC.

2. Use of 4 or More Psychotropics in Children
Shannon Nelson reported that for WC, 168 letters were sent and 10 responses were received, 7 noting that the information was useful, 3 noting that it was not useful.
Bernadette Ueda shared that 325 UHC patients were identified; 207 letters were sent and 109 response forms were received with 65 prescribers responding.

3. **MME Daily Limit of 300 Implementation Date: December 6, 2018**
   Shannon Nelson noted that 62 letters were sent on July 30th to prescribers of WC patients that met the criteria. To date, 8 responses have been received, including 5 finding the information useful who planned to counsel the patient, flagged the patient for monitoring or planned to change the dose. Two found the information not useful, noting that the patient listed was not in their care.

   Bernadette Ueda reported that 45 UHC patients have been identified as meeting the criteria, impacting 56 prescribers.

   Kevin Peterson explained that there were 136 NTC patients meeting the criteria. To date, 38 responses have been received; 4 indicating that the information was useful, 8 planned to counsel the patient.

   Jill Bot reported that no patients in FFS met the criteria.

4. **7 Day Limit in Opioid-Naïve Patients (max of 50 MME per day) Implementation date: October 11, 2018**
   Jill Bot noted that in FFS, 64 letters were sent to prescribers who had patients that met the criteria. 26 responses have been received; 1 noted that the information was not useful.

   Kevin Peterson shared that 82 NTC patients met the criteria, representing 62 prescribers. To date, 24 responses have been received, 11 noting that the information was useful and 9 indicating that they were aware of the issue.

   Bernadette Ueda reported that 1,091 UHC patients met the criteria, representing 963 prescribers. Letters will be sent soon.

   Shannon Nelson noted that there were 36 WC patients who met the criteria and letters were sent on July 30th. To date, 2 responses have been received. One prescriber noted that the patient will be referred to a pain management specialist and the other indicated that prescriptions will be modified going forward.

5. **Adult patients taking stimulants exceeding the FDA-Approved Limits**
   Shannon Nelson reported that there were 132 WC patients meeting the criteria, representing 223 prescribers. Letters were recently sent.

   Bernadette Ueda shared that there were 321 UHC patients meeting the criteria, representing 215 prescribers. Letters are scheduled to be sent soon.

   Kevin Peterson explained that there are no NTC patients meeting the criteria, as these patients had already been reviewed and requests above the FDA-approved limits have been denied.

   Jill Bot shared that no patients in FFS met the criteria.
B. Recommendations for Future Profile Reviews
Letters will be sent in September on concomitant antipsychotic medications in children.
Letters will be sent in October on concomitant mood stabilizers in children.

VII. Prospective DUR
A. New Business
      Draft criteria were reviewed. Board members discussed the role of long-acting
      opioids and agreed that use should be limited to opioid-experienced patients.
      Bernadette Ueda shared that in the second quarter of 2018, there were 1,377 patients
      taking an opioid and 67 of those patients were receiving a long-acting opioid without
      a short-acting agent on record in the previous 60 days. The published study from
      Oklahoma was discussed. Board members requested additional information for
      discussion at the November meeting.

B. Old Business
   1. Review Use of Buprenorphine Post-PA Changes
      Board members reviewed the data regarding the number of unique patients taking
      buprenorphine products in 2017 prior to the changes in the PA criteria and in 2018
      after the changes were in effect. It was noted that there was very little change in the
      number of patients taking buprenorphine after the criteria were removed from the
      preferred product.

VIII. Special Requests from the Department
None.

IX. Future Meeting Dates
November 6, 2018
January 8, 2019
March 12, 2019
May 14, 2019
July 9, 2019
September 10, 2019
November 12, 2019

X. Concerns and Comments from
Board – Concerns were expressed about the November meeting date conflicting with
   elections.
Director – None.
State Representatives- None.
Managed Care Organization Representatives- None.
Public Attendees- Nancy Bell of Pfizer noted that there is a group of stakeholders in
   Nebraska putting together a state-wide campaign for a Tobacco Cessation Awareness Week
   around the Great American Smoke Out in November to increase quit attempts and help
   Nebraska reach the Healthy People 2020 goal of decreasing the number of smokers.

XI. Adjournment
A motion was made by Lynn Carlson with a second from Phil Vuchetich to adjourn at 7:44
   p.m. Vote as follows: Borcher-yes, Carlson-yes, Castillo-yes, Gall-yes, Houghton-yes,
   Kelley-yes, Mattson-yes, Moore-yes, Muffly-yes, Randolph-yes and Vuchetich-yes. Motion
   carried.